European Association of Nuclear Medicine
Budget
€7,895,070
EP Access
1
accredited persons
Staff
8
2.4 FTE
EU Grants
€140,392
Mission & Goals
The EANM is the largest organisation dedicated to nuclear medicine and multi-modality imaging and related subjects in Europe. It has become the umbrella organisation representing the specialty towards European and international institutions. Our vision is to optimise and advance science and education in the area of nuclear medicine for the benefit of public health and humanity within the concept of personalised healthcare. We aim at being the platform for dissemination and discussion of latest advances and improve the exchange of knowledge relating to the diagnosis, treatment and prevention of diseases through the use of unsealed radioactive substances and the properties of stable nuclides in medicine. To achieve this, we conduct scientific meetings, one annual congress, courses, webinars and publish policy and position papers as well as guidance documents. Collaboration with partner societies is a cornerstone of EANM's strategy.
EU Legislative Interests
Europe´s Beating Cancer Plan and all connected initiatives including the EU cancer mission ; SAMIRA Action Plan, and the related European Radioisotopes Valley Initiative ; Pharma strategy and the related European Pharmaceutical Package ; EU Non-Communicable Disease initiative ; Artificial Intelligence Regulation ; European Health Data Space ; Clinical Trials Directive and ACTEU ; European Health Technology Assessment ; Implementation of the BSS Directive ; Professional Qualification Recognition legislation ; Personalised medicine and precision oncology ; Workforce planning, education, mobility and safety ; European Commission Communication on Addressing Medicines Shortages in the EU ; Critical Medicines Alliance and Union List of Critical Medicines; Medical Devices Regulation ; Cardiovascular Health Plan and connected initiatives ; Safe Hearts Plan ; BioTech Act, Critical Medicines Act ; Pharma Legislation
Communication Activities
*Publication of updated EANM Overarching Narrative Position Paper "Nuclear Medicine What it is. Where it goes. What it needs." (February 2026) *Publication of EU REST - Final Report: "Analysis on workforce availability, education and training needs for the quality and safety of medical applications involving ionising radiation in the EU Status and recommendations" (January 2025) *EMA Co-organised Social Media Campaign #ItTakesATeam on shortages (November 2025) *Organisation of 2 EU Policy Symposia during our annual Congress on Healthcare System Readiness and HTA (October 2025) *Organisation of a dedicated Policy Workshop on EANM's priorities and activities during our annual Congress (October 2025) *Organisation of a dedicated EU Projects Track showcasing active EU-funded initiatives during our annual Congress (October 2025) *Publication of SIMPLERAD Final Report: "SAMIRA Study on the Implementation of the Euratom and EU Legal Bases with Respect to the Therapeutic Uses of Radiopharmaceuticals" (December 2024) *Publication of EANM Roadmap 2024-2029 - "Nuclear Medicine Looking Towards 2029" (October 2024) *Organisation of 2 EU Policy Symposium during our annual Congress on the Nuclear Medicine Workforce and on EU Pharma Legislation & Basic Safety Standards (Octobre 2024) *Publication of EANM-NMEU joint communication on the European Pharmaceutical Legislation revision: "Turning the tide – A Critical Call for Unlocking Nuclear Medicine Potential in Europe" (April 2024) *Publication of the EANM Statement on the Union List of Critical Medicines "Rationale for inclusion of radioisotopes" (February 2024) *Publication of EJNMMI Editorial: "The revision of the pharmaceutical legislation — it is time to act for nuclear medicine in Europe" (November 2023) *Publication of EANM-NMEU joint statement on the revision of the European Pharmaceutical Legislation: "Time to Act for Nuclear Medicine" (October 2023) *Publication of EANM Statement on Animal Testing in the EU: "The potential adverse effect of a ban on biomedical research" (July 2023) *Publication within the EJNMMI: "The QuADRANT study: current status and recommendations for improving uptake and implementation of clinical audit of medical radiological procedures in Europe—the nuclear medicine perspective" (May 2023) *Quarterly publication of the EANM Policy Bulletin, a newsletter focusing on nuclear medicine and regulatory/policy topics *Social Media Campaign on Animal Testing in the EU (Summer 2023) *Social Media Campaign on the revision of the EU Pharmaceutical Legislation (Summer 2023) *Organisation of 2 EU Policy Symposium during our annual Congress on Supply & Shortages of Radiopharmaceuticals and on Regulatory Hurdles for Radiopharmaceuticals (Septembre 2023) * Publication of the EANM-EAHP joint statement on "the availability of radiopharmaceuticals in the context of the revision of the general pharmaceutical legislation" (December 2022) * Publication of the EANM Overarching Narrative "Nuclear Medicine. What it is. Where it goes. What it needs. (June 2022) * Publication of the "EANM position on the in-house preparation of radiopharmaceuticals" (December 2021) * Publication of the "EANM Statement for a better inclusion of the particularities of Radiopharmaceuticals within the Review of Directive 2001/83EC on Pharmaceutical Legislation" (December 2021) * Publication of the "EANM Statement: Posology for Radiopharmaceuticals: contradictory legal requirements between BSS Directive 2013/59/Euratom and EMA marketing authorisations schemes" (December 2021) * Joint coalition statement: "Reducing bureaucracy in clinical trials: now is the time! as well as " as well as "Recommendations of the Coalition for Reducing Bureaucracy in Clinical Trials"
Interests Represented
Does not represent commercial interests
Member Of
European Cancer Organisation - https://www.europeancancer.org/ European Alliance for Medical Radiation Protection Research (EURAMED) - https://www.euramed.eu/ European Institute for Biomedical Imaging Research (EIBIR) - https://www.eibir.org/ Coalition for Reducing Bureaucracy in Clinical Trials - https://bureaucracyincts.eu/
Organisation Members
41 national member societies in the field of nuclear medicine: https://eanm.org/the-eanm-community/organisation/member-societies/ Additional "affiliated" member societies, not within the Council of Europe: https://eanm.org/the-eanm-community/organisation/member-societies/ Industry partners: https://eanm.org/eu-global-affairs/partnerships/financial-assessment/
Additional Information
For 2025, financial year is not yet closed - annual closed accounts will be available around Mid-April 2026.
Commissioner Meetings
No recorded meetings with EU commissioners.